Relationships between paediatricians and infant formula milk companies

C M Wright, A J R Waterston

Paediatricians should recognise the influence of infant formula milk companies and avoid intentionally or inadvertently promoting them

The promotion of breast feeding is a high priority for most paediatricians, yet many, inadvertently, assist infant formula milk companies (IFMCs) in their marketing, thereby undermining breast feeding. This article examines how infant formula manufacturers achieve this and how such promotion can be avoided.

WHY THIS IS IMPORTANT

It is now known that the use of infant formula instead of breast milk is one of the most important causes of preventable mortality in infancy world wide.¹⁻³ However, there is growing evidence that this is not just an issue for poorer countries. Research in the United Kingdom has shown associations with increased morbidity,^{4,5} reduced later intelligence quotient (IQ),⁶ and increased risk of adult ill health,⁷ and a recent paper from the United States showed an association with excess infant mortality.⁸ This places the use of infant formula high among the avoidable risks to health to which children in the United Kingdom are exposed. Yet in the United Kingdom, breast feeding rates are stagnant, after encouraging rises in recent decades, and there is a clear social class disparity, which means that children in the poorest families, already facing multiple adversities, predominantly start life without the protective benefits of breast milk.⁹ Globally, breast feeding is also under threat, with signs of reverses in rates of exclusive breast feeding in many countries.¹⁰

WHY INFANT FORMULA MANUFACTURERS SPONSOR PAEDIATRICIANS

Infant formula manufacturers have a duty to their shareholders to maximise sales of their products, which by definition means minimising exposure of infants to breast milk. Hence while publicly stating their commitment to breast feeding, as required by law, IFMCs are, in fact profiting from the failure of breast feeding. With growing

knowledge of the hazards of infant formula, manufacturers need to seek ever more sophisticated ways of promoting their products as scientific and safe. Any link with paediatricians or other health professional is thus likely to enhance their products' credibility and sales. IFMCs are therefore happy to provide funds from their advertising budgets to achieve this. There are three main ways by which IFMCs forge these links with paediatricians: through educational activities, support of a department or organisation, and funding of research.

Sponsorship of an educational event promotes a company and its products at a number of levels. The firm's name is linked to that of the institution on widely distributed publicity, those attending the course receive material such as pens bearing the firm's logo, and all involved will then tend to have subtly enhanced respect for that company and their products. When companies fund clinical activity or support health related organisations, this also conveys an impression of the company as being "health giving" even if their products may cause net harm to children's health.

Research into formula milks, although ostensibly necessary, in fact serves an important role in promoting the use of infant formula, as the results are then used to enhance the impression of their "equivalence" to breast feeding, once compounds present in breast milk, such as "pre-biotics", are added. Every supposed enhancement of an infant formula, which EU law only requires be tested in trials of equivalence to other formulas, can then be advertised as making the formula "even closer to breast milk" even though there is no evidence that any such enhancements have actually increased the safety of formula. Paediatricians also tend to attach great significance to the role of IFMCs in developing specialist formulas, which may be useful for a tiny number of infants, without necessarily

recognising that far more infants suffer because they were deprived of the protective benefits of breast milk by the use of that company's products.

WHY PAEDIATRICIANS SHOULD AVOID IFMC SPONSORSHIP

The relationship between doctors and both their patients and society as a whole is termed a "fiduciary" relationship; doctors have specialised knowledge and expertise and hold the trust of others, which implies a particular duty to avoid conflicts of interest. Sponsorship by its nature creates a conflict of interest. Whether it takes the form of gift items, meals, or help with conference expenses, it creates a sense of obligation and a need to reciprocate in some way. The "gift relationship" thus influences our attitude to the company and its products and leads to an unconscious unwillingness to think or speak ill of them.

Even if individuals are uninfluenced by sponsorship and subsequently act wholly responsibly in relation to breast and formula feeding, by accepting sponsorship or speaking at an IFMC meeting they still lend credibility to the company by the visible association of their name and position with that company. This is why UNICEF and WHO have for many years advocated the complete separation of health professionals from IFMCs at an organisational level. This is a vital step in the promotion of breast feeding, as it is almost impossible for any individual health worker to avoid, or even be aware of, the influence of IFMC promotion. The WHO code remains a vital tool in this respect¹¹ (box 1). The UNICEF Baby Friendly hospital award is potentially achievable by all maternity hospitals in the United Kingdom, and there is evidence¹² that hospitals that are Baby Friendly show improved breast feeding rates compared with those who are not.

It is also worth noting that only 9% of births in England currently occur in Baby Friendly accredited hospitals, although the figure is 54% in Scotland.¹³ Paediatricians who wish to take this up with their chief executive will find a model letter on the Baby Friendly website (www.babyfriendly.org.uk).

ARE PAEDIATRICIANS INFLUENCED?

The willingness of IFMCs to pour money into the support of paediatricians indicates that they believe the link will increase their companies' success. There is an analogy with drug company sponsorship, which also attaches great importance to medical opinion formers (box 2).

Box 1: The WHO code of marketing breast milk substitutes¹¹

Exists to protect and promote breast feeding and to ensure the safe use of breast milk substitutes by provision of adequate information and restricting promotional activities

- Article 5.1: There should be no advertising or other form of promotion to the general public of products within the scope of the code
- Article 6.2: No facility of the healthcare system should be used for the purpose of promoting infant formula or products within the scope of the code. This code does not, however, preclude the dissemination of information to health professionals as provided in article 7.2.
- Article 7.3: No financial or material inducements to promote products within the scope of the code should be offered by manufacturers or distributors to health workers or members of their families, nor should these be accepted by health workers or members of their families

WHA 49.15

Member states should ensure that the financial support for professionals working in infant and young child health does not create conflicts of interest, especially with regards to the WHO/UNICEF Baby Friendly Hospital Initiative

Box 2: *Pharmaceutical Marketing Journal* (quoted in the *Guardian* 5 Oct 2004)

"Seek careful identification of the people you should be working with. The key is to evaluate their views and influence potential, to recruit them to specially designed relationship-building activities and then provide them with a programme of appropriate communications platforms."

A review¹⁴ showed that meetings with pharmaceutical representatives were associated with increased requests by doctors for their drugs to be added to the hospital formulary and to changes in prescribing practice, while attending sponsored educational events and receiving funding were associated with increased prescription rates of the sponsor's medication.

WHAT IS THE EFFECT OF REFUSING SPONSORSHIP?

Since the Royal College of Paediatrics and Child Health (RCPCH) stopped accepting direct sponsorship from IFMCs, there have been no adverse financial effects, despite gloomy predictions. Where a certain amount of sponsorship is routinely available, conference budgets tend to reflect this, in terms of the level of accommodation and catering offered, travel expenses and honoraria paid, leading to the perception that sponsorship is essential. Yet many United Kingdom organisations run successful and affordable meetings using no sponsorship of any kind. The Pakistan Paediatric Association, in one of the poorest countries in the world, refuses all IFMC funding, yet regularly runs large meetings at profit.

WHAT CAN PAEDIATRICIANS DO?

It can be difficult for individuals to navigate the complexities of what

actually constitutes sponsorship and how exactly to define an IFMC. From our experience of this we have developed a draft code of practice (tables 1 and 2) that others might like to draw on in discussion with their colleagues on these

matters. Avoiding IFMC sponsorship can be a lonely and unrewarding business; we suggest that the time has come for UNICEF or the RCPCH to establish the concept of "Baby Friendly" practitioners who, like institutions, could be rewarded symbolically for consistently avoiding IFMC sponsorship.

CONCLUSIONS

If breast feeding, with all its benefits, is to be established as a majority activity, we paediatricians must learn to recognise the elaborate web woven around us by formula manufacturers, which currently ensures our goodwill and support for a product that we may acknowledge, but would mostly not wish to actively promote. Fifty years ago nearly everyone, including doctors, smoked and it was perceived to be a necessary and inescapable part of our culture. Now it is unimaginable that we would smoke in front of our patients or accept gifts from cigarette manufacturers. It is time for a similar shift to take place with respect to formula milk. Just because many mothers currently choose to bottle feed their infants and a tiny number of infants cannot be breast fed, it does not mean we should be seen to be endorsing a product that causes net damage to the health of children. The time has come for paediatricians to recognise the influence of IFMCs, shake off their silken chains, and become truly uncompromised advocates for breast feeding and against the hazards of formula milk.

Table 1 Which types of companies should be avoided

Definitely	Any company whose main product is breast milk substitutes, bottles or teats, e.g. SMA, Milupa, Cow&Gate, Farleys
Arguably	Any company who markets other clinical products using a name clearly identified with breast milk substitutes, e.g. Nestle, Nutricia
Not usually	Any company that, among other products, makes or sells infant formulas, e.g. a supermarket might generally be an acceptable sponsor, but not if this was linked to their promotion of formula milk

Table 2 What sort of sponsorship should be avoided

Within a unit	Reason to be avoided
The use of leaflets or posters displaying IFMC company logos	Promotes the company to public in trusted environment
Support from IFMCs for teaching sessions or meetings	Publicity will associate your unit with the company
Support for staff salaries, equipment, or research	Unit will be indebted to the company, tending to stifle expressions of doubt about their products or practices
As an individual	Reason to be avoided
Accepting gifts of stationery, pens, clinical equipment	You promote the company to your patients by using them
Speaking at meetings visibly badged by IFMCs	Publicity will be used to promote the company and link your name to it
Support for attending a conference or course	You will feel indebted to the company and inclined to expect such support in future

ACKNOWLEDGEMENTS

We are grateful to Nick Spencer, David Stone, and Andrew Radford for commenting on drafts of the manuscript.

Arch Dis Child Fetal Neonatal Ed 2006;**91**:383–385.

doi: 10.1136/adc.2005.072892

.....

Authors' affiliations

C M Wright, PEACH Unit, Department of Child Health, Glasgow University, Glasgow, Scotland, UK

A J R Waterston, Department of Child Health, Newcastle General Hospital, Newcastle upon Tyne, UK

Correspondence to: Professor Wright, PEACH Unit, QMH Tower, Yorkhill Hospitals, Glasgow G3 8SJ, Scotland, UK; cmw7a@clinmed.gla.ac.uk

Competing interests: AJRW is an unpaid adviser to Baby Milk Action which campaigns to reduce unethical marketing by infant formula manufacturers

REFERENCES

- 1 **WHO**. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. WHO Collaborative Study Team on the Role of Breastfeeding in the Prevention of Infant Mortality. *Lancet* 2000;**355**:451–5.
- 2 **Betran AP**, de Onis M, Lauer JA, *et al*. Ecological study of effect of breast feeding on infant mortality in Latin America. *BMJ* 2001;**323**:303–6.
- 3 **Huffman SL**, Zehner ER, Victora C. Can improvements in breast-feeding practices reduce neonatal mortality in developing countries? *Midwifery* 2001;**17**:80–92.
- 4 **Oddy WH**, Sly PD, de Klerk NH, *et al*. Breast feeding and respiratory morbidity in infancy: a birth cohort study. *Arch Dis Child* 2003;**88**:224–8.
- 5 **Wilson A**, Forsyth J, Greene S, *et al*. Relation of infant diet to childhood health: seven year follow up of cohort of children in Dundee infant feeding study. *BMJ* 1998;**316**:21–5.
- 6 **Lucas A**, Morley R, Cole T, *et al*. Breast milk and subsequent intelligence quotient in children born preterm. *Lancet* 1992;**339**:261–4.
- 7 **Singhal A**, Cole TJ, Lucas A. Early nutrition in preterm infants and later blood pressure: two cohorts after randomised trials. *Lancet* 2001;**357**:413–19.
- 8 **Chen A**, Rogan WJ. Breastfeeding and the risk of postneonatal death in the United States. *Pediatrics* 2004;**113**:e435–9.
- 9 **Hamlyn B**, Brooker S, Oleinikova K, *et al*. *Infant feeding 2000*. London: TSO, 2002.
- 10 **UNICEF**. *State of the World's Children*. Oxford: UNICEF, 2005.
- 11 **World Health Organisation**. *International code of marketing of breast milk substitutes*. Geneva: WHO, 1981.
- 12 **Broadfoot M**, Britten J, Tappin DM, *et al*. The Baby Friendly Hospital Initiative and breast feeding rates in Scotland. *Arch Dis Child Fetal Neonatal Ed* 2005;**90**:F114–16.
- 13 **UNICEF**. Baby Friendly accredited health care facilities. UNICEF UK Baby Friendly Initiative. <http://www.babyfriendly.org.uk/home.asp> (news updates 24 Mar 2005 and 31 Mar 0005).
- 14 **Wazana A**. Physicians and the pharmaceutical industry: is a gift ever just a gift? *JAMA* 2000;**283**:373–80.

IMAGES IN PAEDIATRICS.....

doi: 10.1136/adc.2005.091934

Phytophotodermatitis

A 6 year old boy presented to the accident and emergency department with sunburn and widespread blistering lesions on his hands, lower arms, legs, back, and trunk (see fig 1). There was complete sparing of the area covered by his shorts and shoes. The lesions were not particularly itchy and he was afebrile and otherwise well. Four hours previously he had been swimming in a local lake and playing in the undergrowth beside it.

A diagnosis of phytophotodermatitis, probably caused by contact with giant hogweed, was made. The blistering settled well with a course of oral prednisolone and topical steroid ointment, leaving areas of hyperpigmentation. Of note to paediatricians are cases where phytophotodermatitis has been mistaken for child abuse.^{1 2}

Plants have been known to cause hyperpigmentation for thousands of years, but the term “phytophotodermatitis”, emphasising the need for both plants and light to cause the reaction, was only introduced in 1942.³ Psoralen

isomers called furocoumarins, found in a wide range of plants such as bergamot, citrus fruits, parsnips, and species of Umbelliferae (celery, cow parsley, and giant hogweed), form phototoxic compounds on exposure to UV-A radiation.⁴ This leads to damage to epidermal cells resulting in erythema, blistering, and hyperpigmentation. The discovery

Figure 1 Blistering on left hand. Consent was obtained for publication of this figure.

of this phenomenon led to development of photomedicine, which established the therapeutic effectiveness of psoralens in combination with high intensity UV irradiation. PUVA is currently used in the treatment of severe psoriasis, mycosis fungoides, and other skin diseases.⁵

R E Klaber

Barnet & Chase Farm NHS Trust, London, UK;
bobklaber@hotmail.com

Competing interests: none declared

References

- 1 **Hill PF**, Pickford M, Parkhouse N. Phytophotodermatitis mimicking child abuse. *J R Soc Med* 1997;**90**:560–1.
- 2 **Klaber MR**. Phytophotodermatitis mimicking child abuse. *J R Soc Med* 1998;**91**:58.
- 3 **Klaber R**. Phytophotodermatitis. *Br J Dermatol* 1942;**54**:193–211.
- 4 **Lutchman L**, Inyang V, Hodgkinson D. Phytophotodermatitis associated with parsnip picking. *J Accid Emerg Med* 1999;**16**:453–4.
- 5 **Pathak MA**, Fitzpatrick TB. The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD. *J Photochem Photobiol B* 1992;**14**:3–22.